CureVac says secondary considerations of nonobviousness not untimely
MLex Summary: An October expert report that detailed eight secondary considerations of nonobviousness is neither untimely nor unfair, CureVac argues. At issue is a motion by Pfizer and BioNTech to strike...To view the full article, register now.
Already a subscriber? Click here to view full article